Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 42,300
-250 (-0.59%)
At close: Sep 17, 2026
KRX:317450 Revenue
Myung In Pharmaceutical LTD. had revenue of 76.11B KRW in the quarter ending June 30, 2026, with 5.40% growth. This brings the company's revenue in the last twelve months to 293.03B, up 4.42% year-over-year. In the year 2025, Myung In Pharmaceutical LTD. had annual revenue of 287.25B with 6.61% growth.
Revenue (ttm)
293.03B
Revenue Growth
+4.42%
P/S Ratio
2.11
Revenue / Employee
874.72M
Employees
335
Market Cap
617.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.25B | 17.82B | 6.61% |
| Dec 31, 2024 | 269.43B | 27.10B | 11.18% |
| Dec 31, 2023 | 242.34B | 16.51B | 7.31% |
| Dec 31, 2022 | 225.83B | 16.58B | 7.92% |
| Dec 31, 2021 | 209.25B | 21.41B | 11.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Dong-A Socio Holdings | 1.52T |
| Samsung Epis Holdings | 1.51T |
| JW Pharmaceutical | 820.86B |
| ALTEOGEN | 254.01B |
| Lunit | 91.82B |
| Onconic Therapeutics | 82.17B |